BioVie (BIVI)

• Market cap: $9.35M
• 1 day: 0.81%
• 5 days: -2.36%
• 1 month: 0.81%
• 3 months: -31.11%
• 6 months: -82.21%
• Year to date: -6.77%
• 1 year: -92.83%
• 5 years: -99.96%
• 10 years: -99.88%
• Sector: Healthcare
• Industry: Biotechnology

About: BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Employees: 13